Alphamab Oncology (HKEX-listed) disclosed a share buyback executed on 9 September 2026, repurchasing 118,000 ordinary shares on-market at prices ranging from HK$8.27 to HK$8.45 per share. The transaction amounted to HK$0.99 million, implying a volume-weighted average price of HK$8.39.

Following the buyback, the number of issued shares (excluding treasury shares) declined by 0.0122% to 967.55 million, while treasury shares increased to 6.83 million. The total issued share capital remained unchanged at 974.38 million shares.

The purchase was made under the repurchase mandate approved on 12 June 2026, which authorises the company to buy back up to 96.85 million shares. Cumulative repurchases under this mandate now total 959,000 shares, equivalent to 0.099% of the issued share count at the mandate’s approval date.

In accordance with Hong Kong listing rules, Alphamab Oncology is restricted from issuing new shares or disposing of treasury shares until 9 October 2026.